The MARIPOSA study represents a pivotal phase in advancing precision oncology for patients with EGFR-mutant non–small cell lung cancer (NSCLC). Over the past decade, third-generation tyrosine kinase inhibitors (TKIs) like osimertinib have improved patient outcomes, yet resistance remains nearly universal.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Hatim
Contact Hatim, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack